 Prealbumin
"Prealbumin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease.
| Descriptor ID |
D011228
|
| MeSH Number(s) |
D12.776.034.841.450 D12.776.124.727.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prealbumin".
Below are MeSH descriptors whose meaning is more specific than "Prealbumin".
This graph shows the total number of publications written about "Prealbumin" by people in this website by year, and whether "Prealbumin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2006 | 1 | 2 | 3 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 3 | 3 | 6 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Prealbumin" by people in Profiles.
-
Soman P, Cuddy SAM, Gillmore JD, Sarswat N, Judge DP, Cappelli F, Stern LK, Wright R, Akinboboye O, Obici L, Bhatt K, Xiong K, Castaño A, Chen C, Falvey H, Pecoraro ML, Tamby JF, Sinha U, Fox JC, Shah K, Grodin JL, Ambardekar AV, Alexander KM, Khouri MG, Cheng RK. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 May 01; 11(5):446-454.
-
Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, Gillmore JD, Grodin JL, Mitchell JD, Mooney D, Nativi-Nicolau J, Poulsen SH, Ruberg FL, Chen C, Ji A, Siddhanti S, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Maurer MS, Cheng RK. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 05; 32(5):864-876.
-
Sarswat N, Ambardekar AV, Alexander KM, Cuddy SA, Stern L, Poulsen SH, Tschöpe C, Sekijima Y, Sheikh FH, Griffin JM, Judge DP, Gillmore J, Masri A. Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM. Future Cardiol. 2026 Feb; 22(2):119-133.
-
Bui QM, McCain J, Allen LA, Adler ED, Anderson C, Bloss C, Rabin BA, Urey MA. Living with Transthyretin amyloid cardiomyopathy from a patient perspective. BMC Cardiovasc Disord. 2025 11 12; 25(1):802.
-
Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, Ruberg FL. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2026 Feb 10; 87(5):549-565.
-
Masri A, Judge DP, Ruberg FL, Gillmore JD, Grodin JL, Obici L, Maurer MS, Fontana M, Poulsen SH, van der Meer P, Cheng RK, Cuddy SAM, Ambardekar AV, Xiong K, Cao X, Murtagh G, Siddhanti S, Castaño A, Tamby JF, Fox JC, Alexander KM, Witteles R. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. J Am Coll Cardiol. 2026 Feb 10; 87(5):490-501.
-
Hussain Y, Malhotra S, Sperry BW, Shu F, Ananthasubramaniam K, Desai U, Egolum U, Fernandez J, Freimer M, Mauricio E, Quan D, Small R, Capocelli K, Roblin S, Bender S, Jay PY, Yureneva E, Zolty R. Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study. Ann Med. 2025 Dec; 57(1):2537347.
-
Dasgupta N, Poulsen SH, Emdin M, Ambardekar AV, Shah KB, Hennum L, Marwah R, Allison M, Shivanna P, Siddhanti S, Tamby JF, Falvey H, Grodin JL. Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. Am J Cardiovasc Drugs. 2025 Nov; 25(6):829-839.
-
Maurer MS, Judge DP, Gillmore JD, Garcia-Pavia P, Masri A, Cappelli F, Alexander KM, Sarswat N, Grogan M, Ambardekar AV, Ducharme A, Poulsen SH, Lam K, Obici L, Soman P, Rao S, Tamby JF, Castaño A, Fox JC, Adam B, Chepyala SR, Poland B, Sinha U, Fontana M. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
-
Jacoby E, Quan D, Todd E, Shortt J, Smith H, Rafaels N, Crooks K. Prevalence of Pathogenic Transthyretin Gene Variants in the Rocky Mountain Region. Muscle Nerve. 2025 Feb; 71(2):252-256.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|